Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2025)

Karyopharm Therapeutics (KPTI) reported Non-Current Debt of $94.8 million for Q4 2025, little changed on a YoY basis from $94.6 million in Q4 2024, and up 12.99% quarter-over-quarter from $83.9 million in Q3 2025.

Karyopharm Therapeutics (KPTI) Non-Current Debt (2024 - 2025) Analysis & Trends

Karyopharm Therapeutics has reported Non-Current Debt for 2 years, with the latest figure at $94.8 million in Q4 2025.

  • For the quarter ending Q4 2025, Non-Current Debt changed 0.2% year-over-year to $94.8 million; the trailing twelve-month figure through Dec 2025 stood at $94.8 million (changed 0.2% YoY), and the FY2025 full-year result was $94.8 million, changed 0.2% from the prior year.
  • Non-Current Debt for Q4 2025 stood at $94.8 million, up from $83.9 million in the prior quarter.
  • The five-year high for Non-Current Debt was $95.2 million in Q1 2025, with the low at $83.9 million in Q3 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Alterity Therapeutics 762,369.55 Bn 762,369.51 Bn - -
2 Belite Bio 55,096.00 Bn 55,096.00 Bn - -
3 Quantum Biopharma 17,755.80 Bn 17,755.79 Bn - -
4 Legend Biotech 3,486.00 Bn 3,485.71 Bn 242.10 Mn 319.10 Mn
5 Akari Therapeutics 1,737.42 Bn 1,737.41 Bn - -
6 Evaxion A 1,551.28 Bn 1,551.26 Bn - -
7 Psyence Biomedical 227.32 Bn 227.31 Bn - -
8 Vertex Pharmaceuticals 110.84 Bn 103.59 Bn 2.59 Bn -
9 Abivax 91.71 Bn 91.71 Bn - -
10 Karyopharm Therapeutics 95.31 Mn 31.56 Mn 32.74 Mn 94.80 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 94.80 Mn
Dec 31, 2025 94.80 Mn
Sep 30, 2025 83.90 Mn
Sep 30, 2025 83.90 Mn
Jun 30, 2025 89.57 Mn
Jun 30, 2025 89.57 Mn
Mar 31, 2025 95.20 Mn
Mar 31, 2025 95.20 Mn
Dec 31, 2024 94.60 Mn
Dec 31, 2024 94.60 Mn
Sep 30, 2024 94.11 Mn
Sep 30, 2024 94.11 Mn
Jun 30, 2024 93.52 Mn
Jun 30, 2024 93.52 Mn